Zydus Lifesciences gets USFDA nod to market generic drug

The company has received the final approval for Levothyroxine Sodium for Injection in strength of 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial from the US Food and Drug Administration (USFDA), the drug firm said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RP4jW5N
via IFTTT